| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4353 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4353 |
| filingDate |
2004-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2014-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-101387988-B1 |
| titleOfInvention |
CCI-779 for the treatment of mantle cell lymphoma |
| abstract |
The present invention relates to the use of rapamycin 42-ester (CCI-779) of 3-hydroxy-2- (hydroxymethyl) -2-methylpropionic acid in the treatment or inhibition of mantle cell lymphoma.n n n Mantle Cell Lymphoma, CCI-779, Rapamycin 42-ester |
| priorityDate |
2003-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |